KalVista Pharmaceuticals (NASDAQ:KALV) Trading Up 5.1% – Here’s Why

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) rose 5.1% on Tuesday . The stock traded as high as $16.00 and last traded at $15.94. Approximately 390,593 shares were traded during trading, a decline of 59% from the average daily volume of 962,275 shares. The stock had previously closed at $15.17.

Analyst Ratings Changes

A number of research firms recently commented on KALV. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a report on Thursday, December 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, October 8th. Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 3rd. Citizens Jmp decreased their target price on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research note on Tuesday, November 11th. Finally, Wall Street Zen raised KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $27.29.

KalVista Pharmaceuticals Stock Performance

The firm has a market cap of $802.48 million, a price-to-earnings ratio of -4.01 and a beta of -0.14. The firm’s fifty day moving average price is $13.69 and its 200-day moving average price is $13.38. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.04. The business had revenue of $13.69 million during the quarter, compared to analysts’ expectations of $6.03 million. Analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 10,940 shares of the business’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $13.45, for a total value of $147,143.00. Following the transaction, the chief executive officer directly owned 416,189 shares of the company’s stock, valued at approximately $5,597,742.05. The trade was a 2.56% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Brian Piekos sold 4,471 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $13.45, for a total transaction of $60,134.95. Following the completion of the sale, the chief financial officer directly owned 10,529 shares in the company, valued at approximately $141,615.05. The trade was a 29.81% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 31,329 shares of company stock worth $437,371. 4.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Tudor Investment Corp ET AL purchased a new stake in shares of KalVista Pharmaceuticals in the third quarter valued at approximately $24,360,000. Parkman Healthcare Partners LLC lifted its holdings in KalVista Pharmaceuticals by 155.5% in the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after acquiring an additional 1,055,940 shares during the period. Ameriprise Financial Inc. boosted its position in shares of KalVista Pharmaceuticals by 2,258.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock worth $10,685,000 after purchasing an additional 905,053 shares in the last quarter. Freestone Grove Partners LP purchased a new position in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $8,580,000. Finally, Schroder Investment Management Group lifted its stake in shares of KalVista Pharmaceuticals by 108.7% in the third quarter. Schroder Investment Management Group now owns 1,158,457 shares of the specialty pharmaceutical company’s stock valued at $14,145,000 after purchasing an additional 603,499 shares during the period.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.